Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IPILIMUMAB Cause Chronic kidney disease? 45 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 45 reports of Chronic kidney disease have been filed in association with IPILIMUMAB (YERVOY). This represents 0.1% of all adverse event reports for IPILIMUMAB.

45
Reports of Chronic kidney disease with IPILIMUMAB
0.1%
of all IPILIMUMAB reports
11
Deaths
30
Hospitalizations

How Dangerous Is Chronic kidney disease From IPILIMUMAB?

Of the 45 reports, 11 (24.4%) resulted in death, 30 (66.7%) required hospitalization, and 5 (11.1%) were considered life-threatening.

Is Chronic kidney disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IPILIMUMAB. However, 45 reports have been filed with the FAERS database.

What Other Side Effects Does IPILIMUMAB Cause?

Death (3,710) Malignant neoplasm progression (3,296) Diarrhoea (2,557) Off label use (2,097) Colitis (1,988) Pyrexia (1,796) Rash (1,556) Fatigue (1,447) Intentional product use issue (1,329) Nausea (1,169)

What Other Drugs Cause Chronic kidney disease?

OMEPRAZOLE (35,759) ESOMEPRAZOLE (35,281) LANSOPRAZOLE (32,517) PANTOPRAZOLE (28,127) DEXLANSOPRAZOLE (15,973) EMTRICITABINE\TENOFOVIR DISOPROXIL (10,248) TENOFOVIR DISOPROXIL (7,230) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (5,861) RABEPRAZOLE (4,773) ESOMEPRAZOLE\NAPROXEN (2,714)

Which IPILIMUMAB Alternatives Have Lower Chronic kidney disease Risk?

IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE IPILIMUMAB vs IPRATROPIUM IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS IPILIMUMAB vs IPTACOPAN IPILIMUMAB vs IRBESARTAN

Related Pages

IPILIMUMAB Full Profile All Chronic kidney disease Reports All Drugs Causing Chronic kidney disease IPILIMUMAB Demographics